Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

12.29EUR
11:35am EDT
Change (% chg)

€0.04 (+0.29%)
Prev Close
€12.26
Open
€12.36
Day's High
€12.39
Day's Low
€12.07
Volume
152,253
Avg. Vol
177,669
52-wk High
€16.20
52-wk Low
€10.00

ABLX.BR

Chart for ABLX.BR

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.93
Market Cap(Mil.): €746.46
Shares Outstanding(Mil.): 60.91
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): -- 41.55 39.69
EPS (TTM): -1.00 -- --
ROI: -45.80 -9.57 14.44
ROE: -105.52 -9.91 15.49

Blockbuster hopes grow for Ablynx drug backed by AbbVie

Ablynx's hopes for a potential multibillion-dollar drug were boosted on Thursday by strong clinical trial results in rheumatoid arthritis, vindicating a $175 million bet placed on the product by U.S. pharma group AbbVie in 2013.

Jul 07 2016

INTERVIEW-Blockbuster hopes grow for Ablynx drug backed by AbbVie

July 7 Ablynx's hopes for a potential multibillion-dollar drug were boosted on Thursday by strong clinical trial results in rheumatoid arthritis, vindicating a $175 million bet placed on the product by U.S. pharma group AbbVie in 2013.

Jul 07 2016

BRIEF-Ablynx announces positive topline results ANTI-IL-6R nanobody

* Announces positive topline results from a phase IIb study of its ANTI-IL-6R nanobody, vobarilizumab (ALX-0061), as a monotherapy in rheumatoid arthritis (RA)

Jul 07 2016

BRIEF-Vectura says Ablynx to exercise a license option on Fox device

* Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Jun 28 2016

BRIEF-Van Herk Investments announce 3.02 pct shareholding in Ablynx

* Van Herk Investments announce 3.02 pct shareholding in Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Jun 16 2016

BRIEF-Ablynx successfully raises 74.2 mln euros

* Announced on Wednesday that it has raised 74.2 million euros ($83.1 million) through a private placement of new shares via an accelerated book building procedure announced on June 1, 2016

Jun 02 2016

BRIEF-Ablynx to raise capital through private placement of new shares

* To raise gross proceeds of up to approximately 60 million euro ($67.0 million)

Jun 01 2016

BRIEF-Ablynx to present a post-hoc analysis of the PHASE II TITAN study with caplacizumab

* Ablynx to present a post-hoc analysis of the Phase II TITAN study with caplacizumab in acquired TTP patients at the 21st congress of the European hematology association

May 26 2016

Ablynx burns more cash in first-quarter on higher R&D costs

Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs.

May 12 2016

Ablynx burns more cash in Q1 on higher R&D costs

May 12 Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs.

May 12 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.